Table 3 Multivariate analysis of the overall survival and progression-free survival in 886 patients with invasive breast cancer

From: Clinical significance of CD151 overexpression in subtypes of invasive breast cancer

 

Overall survival

Disease-free survival

Prognostic factor

Hazard ratio (95% CI)

P -value

Hazard ratio (95% CI)

P -value

CD151 expression

 Low

    

 High

1.65 (1.03-2.59)

0.034

1.15 (0.814-1.634)

0.421

AJCC stage

 I

    

 II

3.57 (1.791-7.103)

<0.001

1.63 (1.072-2.473)

0.022

 III

11.5 (5.724-23.17)

<0.001

4.25 (2.766-6.531)

<0.001

Subtype

 Luminal A

    

 Luminal B

1.63 (0.926-2.868)

0.090

1.44 (0.980-2.109)

0.063

 HER2

2.49 (1.518-4.091)

<0.001

1.40 (0.941-2.092)

0.097

 TNBC

3.08 (1.969-4.815)

<0.001

1.18 (0.831-1.675)

0.356

Adjuvant chemotherapy

 No

    

 Yes

0.30 (0.195-0.451)

<0.001

0.88 (0.584-1.309)

0.514

  1. Abbreviations: AJCC=American Joint Committee on Cancer; CI=confidence interval; HER2=human epidermal growth factor receptor 2; TNBC=triple-negative breast cancer. Statistically significant P-values (P<0.05) are shown in bold.
Back to article page